You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5423 Results
Document
Oct 2020
These evidence-based recommendations are from ColonCancerCheck, Ontario’s colorectal cancer screening program. Surveillance recommendations are...
Find answers to frequently asked questions about ColonCancerCheck’s post-polypectomy surveillance recommendations.
Document
Oct 2020
Document
Oct 2020
Document
Oct 2020
Document
Oct 2020
Document
Oct 2020
Document
Oct 2020
Document
Oct 2020
Cancer facts
Jan 2016
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Trastuzumab (Biosimilar) with Tucatinib and Capecitabine - Metastatic Breast Cancer
Exceptional Access Program
    tucatinib - in combination with trastuzumab and capecitabine for advanced breast cancer, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capecitabine,
tucatinib,
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025

Pages